Rexahn Pharmaceuticals, Inc.
(NYSE Amex Equities : RNN)

( )
RNN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.31%85.371.3%$1334.67m
AMGNAmgen Inc.
0.00%201.561.2%$603.80m
GILDGilead Sciences, Inc.
0.00%68.250.9%$535.10m
LOXOLoxo Oncology Inc
-0.03%233.7012.7%$517.58m
BIIBBiogen Inc.
-0.51%337.221.3%$412.55m
VRTXVertex Pharmaceuticals Incorporated
-2.06%189.891.9%$326.56m
ILMNIllumina, Inc.
0.53%303.893.5%$304.82m
REGNRegeneron Pharmaceuticals, Inc.
-0.88%401.212.6%$300.94m
ALXNAlexion Pharmaceuticals, Inc.
0.92%118.082.0%$225.36m
EXASExact Sciences Corporation
4.79%79.7125.3%$149.33m
AAgilent Technologies, Inc.
0.45%71.641.5%$147.28m
INCYIncyte Corporation
2.23%76.882.5%$147.19m
SRPTSarepta Therapeutics, Inc.
-1.30%118.7215.4%$129.31m
LGNDLigand Pharmaceuticals Incorporated
-1.00%111.7823.1%$119.93m
NBIXNeurocrine Biosciences, Inc.
-2.15%89.325.1%$95.56m

Company Profile

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; RX-5902 or Supinoxin for metastatic triple negative breast cancer; and RX-0201 or Archexin for renal cell carcinoma, glioblastoma, ovarian, stomach, and pancreatic cancer. It also develops nano-based drug delivery systems. It also develops nano-based drug delivery systems. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.